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Methodology 6 
This guideline was compiled according to the BSH process at b-s-h.org.uk. The 7 
Grading of Recommendation Assessment, Development and Evaluation (GRADE) 8 
nomenclature was used to evaluate levels of evidence and to assess the strength of 9 
the recommendations. The GRADE criteria can be found at 10 
http//:www.gradeworkinggroup.org. 11 
Literature review details 12 
The literature review was conducted on 2nd March 2017. Databases searched 13 
include MEDLINE(OVID), Embase (OVID) and CENTRAL(The Cochrane library) 14 
using search terms (and relevant MESH terms) polycythaemia vera, erythrocytosis, 15 
familial, high oxygen affinity haemoglobin, defects of oxygen sensing pathway, 16 
diagnosis, investigation, molecular, mutation, JAK2,MPL, CALR, bone marrow, red 17 
cell mass, erythropoietin, risk, management, treatment, cytoreduction, venesection, 18 
hydroxyurea, interferon, busulfan, pipobroman, radioactive phosphorus, aspirin, 19 
anagrelide, ruxolitinib, thrombosis, haemorrhage, pregnancy, pruritus, surgery and 20 
management. The search covered the period from 2005  the date of last version of 21 
the guideline, to February week 3 2017. Exclusions included articles not in English, 22 
studies not in humans, single case reports and case series of under 5 cases. A total 23 
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of 6062 articles were identified which with exclusions and duplications resulted in 1 
1215 articles which were reviewed. 2 
Review of manuscript 3 
Review of the manuscript was performed by the British Society for Haematology 4 
(BSH) Guidelines Committee General Haematology Task Force, the BSH Guidelines 5 
Committee and the General Haematology Sounding Board of BSH. It was also on 6 
the members section of the BSH website for comment. A patient representative from 7 
MPN-Voice (www.mpnvoice.org.uk) participated in the guideline writing meeting. The 8 
guideline has been reviewed by MPN-Voice; this organisation does not necessarily 9 
approve or endorse the contents. 10 
Introduction 11 
The previous guideline was published in 2005 (McMullin, Bareford et al. 2005) with 12 
an amendment in 2007(McMullin, Reilly et al. 2007) to update the diagnostic criteria 13 
following the discovery of the JAK2 mutation in patients with polycythaemia vera 14 
(PV). Since that time there has been a considerable amount of research in the area 15 
concerning diagnostics, risk stratification, new agents and reinvestigation of existing 16 
agents. It was therefore decided to evaluate the literature to formulate guidance on 17 
the diagnostic pathway for erythrocytosis, risk stratification of polycythaemia vera 18 
(PV), management of PV including specific situations and the management of 19 
secondary erythrocytosis.  Here we provide evidence-based guidance on diagnosis, 20 
risk stratification and management of PV. Our review of the evidence  led us to some 21 
differences in diagnostic criteria  and risk stratification  than have been proposed by 22 
other international organisations. We discuss the reasons for this. An accompanying 23 
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guideline looks at management of specific situations in PV and management of 1 
secondary erythrocytosis. 2 
The diagnostic pathway for investigation of an erythrocytosis  3 
Patients with a persistently raised venous haematocrit (Hct) (>0.52 males, >0.48 4 
females) should be investigated. As suggested in our previous guideline and 5 
confirmed in recent literature, Hct has been consistently shown to perform better in 6 
identifying patients with a raised red cell mass than haemoglobin concentration 7 
(Alvarez-Larrán, Pereira et al. 2012, Ancochea, Alvarez-Larrán et al. 2014).   8 
Patients should be investigated according to the proposed algorithm (Fig. 1).  9 
Investigation requires knowledge of diagnostic criteria for both PV and potential 10 
secondary causes of erythrocytosis (Tables I and II).  A detailed history, examination 11 
and stage 1 investigations (listed below) should identify a potential cause in the 12 
majority of patients, although a proportion will require more extensive testing and in 13 
some a cause cannot be found (idiopathic erythrocytosis).  The potential for dual 14 
pathology should also be considered.  15 
Initial assessment  16 
Clinical History and Examination 17 
A detailed clinical history and examination are essential and, in the absence of a 18 
molecular marker of disease, will determine further investigations and management.  19 
Particular attention should be paid to the drug history (prescribed and recreational), 20 
smoking, alcohol consumption and body habitus.  Systematic questioning should 21 
elicit symptoms related to other potential secondary causes of erythrocytosis (see 22 
Table II).  A proportion of patients, who have a clear secondary cause for their 23 
erythrocytosis, may not need any further investigations.   24 
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Stage 1 Investigations 1 
Full blood count / blood film 2 
The full blood count analysis will not only confirm a raised Hct but will also identify 3 
neutrophilia and thrombocytosis, which are common in JAK2 V617F-positive PV and 4 
part of the criteria for JAK2-negative PV (Table 1).  As smokers have a significantly 5 
higher neutrophil count than non-smokers (Whitehead, Robinson et al. 1995) a 6 
neutrophilia is defined as >12.5 ×109/l in this patient group. 7 
A blood film should be reviewed in all patients to look for any atypical features.  In 8 
those with confirmed PV, abnormalities such as circulating blasts, leucoerythroblastic 9 
features and monocytosis would be indications for bone marrow assessment.      10 
Renal and Liver Function 11 
A number of renal and hepatic diseases can cause erythrocytosis.  Serum calcium 12 
levels should also be determined to exclude a parathyroid adenoma/carcinoma, 13 
which rarely causes secondary erythrocytosis. 14 
Arterial oxygen saturation (SaO2) / carboxyhaemoglobin 15 
Identifying tissue hypoxia, a cause of secondary erythrocytosis, can be achieved 16 
most simply by using pulse oximetry in the clinic.  An SaO2 of <92% has been 17 
shown to be associated with an absolute erythrocytosis (Berlin 1975). Clinicians 18 
should however be aware of three situations of hypoxic erythrocytosis where this 19 
testing is unreliable and will give a normal result.  These are carbon monoxide 20 
poisoning, high oxygen affinity haemoglobins and sleep apnoea syndrome.  Those 21 
with suspected high oxygen affinity haemoglobins should undergo genetic testing as 22 
described below.  In those with suspected sleep apnoea (heavy snoring with daytime 23 
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somnolence or increased body mass index >30 kg/m2), referral should be made to a 1 
respiratory or sleep physician. 2 
Carboxyhaemoglobin (COHb) levels are significantly higher in smokers compared 3 
with non-smokers and cigarette consumption has been shown to be directly related 4 
to COHb levels (Castleden and Cole 1975). Testing can therefore be performed at 5 
baseline where smoking is suspected.   6 
Serum Ferritin 7 
Low serum ferritin levels are common in PV patients and iron deficiency can mask 8 
the presentation of PV giving a misleadingly low Hct because iron deficiency limits 9 
erythropoiesis and hypochromic microcytosis develops.   10 
Serum Erythropoietin 11 
Erythrocyte production is controlled by the hormone erythropoietin (EPO). 12 
Measurement of serum EPO can provide information on potential causes of 13 
erythrocytosis and help stratify further testing (see Fig.1).  EPO levels are commonly 14 
high in hypoxic conditions or when erythrocytosis is secondary to exogenous 15 
administration or endogenous overproduction.  In contrast EPO levels are typically 16 
low in PV, although their diagnostic utility in this setting is limited in the era of JAK2 17 
mutation testing (Ancochea, Alvarez-Larrán et al. 2014).  18 
JAK2 V617F mutational analysis 19 
The identification of JAK2 mutations in almost all PV patients has revolutionised the 20 
diagnosis of PV.  The JAK2 V617F mutation can be found in over 95% of PV 21 
patients (James, Ugo et al. 2005) and an exon 12 mutation in most remaining 22 
patients (Scott, Tong et al. 2007). Testing for JAK2 V617F in peripheral blood is 23 
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sensitive and bone marrow samples are not required to identify this (Takahashi, 1 
Patel et al. 2013).  Testing for JAK2 V617F  is advised as a stage 1 investigation and 2 
should confirm the diagnosis the vast majority of PV patients.  Separate guidance is 3 
available for assays used for detection of JAK2 mutations (Bench, White et al. 2013). 4 
Further Investigations in JAK2 V617F-negative erythrocytosis 5 
Further investigations are warranted in those patients with a persistent, significant 6 
erythrocytosis if JAK2 V617F studies are negative and a secondary cause is not 7 
immediately apparent (See Figure 1).  Secondary causes must be considered since 8 
PV is rare in the absence of a JAK2 V617F mutation. 9 
Red Cell Mass studies 10 
Patients with Hct >0.60 (males) or >0.56 (females) can be assumed to have an 11 
absolute erythrocytosis, but in others red cell mass (RCM) studies can be helpful to 12 
confirm an absolute erythrocytosis. A RCM more than 25% above the mean 13 
predicted value is diagnostic of an absolute erythrocytosis (Pearson, Guthrie et al. 14 
1995). Those with a raised Hct but a RCM within the normal range have an apparent 15 
erythrocytosis.  A relative erythrocytosis, found in states of dehydration, can be 16 
confirmed when the RCM is within the normal range and plasma volume is below 17 
normal.  Patients with a relative or apparent erythrocytosis require no further 18 
investigation. It is noted however that due to the many drawbacks of this test 19 
including cost and labour, access to RCM studies is variable nationally.   20 
Abdominal Ultrasound  21 
Radiological splenomegaly is a minor criterion for JAK2 V617F-negative PV (Table 22 
1) and ultrasound is the simplest method for detection.  Abdominal ultrasound can 23 
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also exclude secondary causes of erythrocytosis, particularly renal and hepatic 1 
pathology including hepatocellular carcinoma.  .  2 
Further testing can be stratified according to the EPO level measured during stage 1 3 
investigations. 4 
Normal or low EPO level 5 
JAK2 exon 12 analysis 6 
Compared with JAK2 V617F, patients with exon 12 mutated- PV tend to be younger, 7 
with higher haemoglobin concentrations, lower white blood cell (WBC) and platelet 8 
counts, and isolated an isolated increase in erythropoiesis without granulocytic or 9 
megakaryocytic morphological abnormalities (Scott, Tong et al. 2007, Passamonti, 10 
Elena et al. 2011).  In contrast to JAK2 V617F testing, a discrepancy between exon 11 
12 mutant allele burden in bone marrow and peripheral blood has occasionally been 12 
described (Kjær, Westman et al. 2012).  13 
Bone marrow biopsy 14 
Bone marrow histology may be helpful in distinguishing PV from secondary 15 
erythrocytosis (Thiele, Kvasnicka et al. 2005). Bone marrow aspiration in PV typically 16 
reveals markedly increased erythropoiesis with moderate to marked increase in 17 
granulopoiesis and megakaryopoiesis; widely variable megakaryocyte size, including 18 
large forms with hyperlobated nuclei; and absent iron stores. The bone marrow 19 
trephine biopsy sections show hypercellularity; trilineage expansion of haemopoiesis 20 
(rarely preferentially erythroid) and normoblastic erythropoiesis. Granulocytic 21 
maturation may be left-shifted and disorderly; megakaryocytes show increased 22 
variation in size, often with a predominance of large forms with uneven or reduced 23 
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nuclear lobulation, and megakaryocyte clusters are common. Reticulin is increased 1 
in a minority of patients (up to WHO grade 1 in most cases). 2 
Presence of an acquired genetic abnormality is a major criterion for JAK2- negative 3 
PV and the presence of an abnormal karyotype can therefore support this diagnosis. 4 
An acquired LNK mutation would also support the diagnosis.   More recently 5 
mutations in a number of other genes, most commonly TET2 and DNMT3A, have 6 
been reported in PV (Delic, Rose et al. 2016) These gene mutations are not, 7 
however, disease specific and have also been reported in healthy individuals 8 
(Genovese, Kähler et al. 2014, Jaiswal, Fontanillas et al. 2014) limiting their 9 
application in the diagnostic setting, particularly when found in isolation.   10 
High EPO level 11 
A raised EPO level should lead to a thorough search for secondary causes of 12 
erythrocytosis (Table 2), which may require additional supplementary investigations 13 
(Figure 1).  14 
Imaging 15 
Further imaging (e.g. CT head and neck) is indicated in this setting if a cause for the 16 
high EPO has not been identified.  Imaging should aim to exclude rare tumours such 17 
as a cerebellar haemangioblastoma, phaeochromocytoma, meningioma or a 18 
parathyroid tumour, all of which can rarely cause erythrocytosis. 19 
Gene sequencing for congenital erythrocytosis 20 
A number of germline mutations in genes involved in oxygen sensing, erythropoiesis 21 
and oxygen transport have now been implicated in patients with otherwise 22 
unexplained erythrocytosis.  These include mutations in the EPO receptor and genes 23 
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in the oxygen sensing pathway (VHL, EGLN1, EPAS1), high oxygen affinity 1 
haemoglobinopathies caused by mutations in the globin genes HBA1, HBA2, HBB, 2 
and 2,3-bisphosphoglycerate deficiency as a result of BPGM mutations (Bento, 3 
Percy et al. 2014). These patients can present with low, normal or high EPO levels; 4 
high affinity haemoglobins and 2,3-BPG deficiency also cause a left shift of the 5 
oxygen dissociation curve. In the past this group of mutations were detected by 6 
Sanger sequencing of individual genes, in an order directed by EPO levels and P50 7 
analysis, but this approach is labour-intensive and time-consuming (Bento, Percy et 8 
al. 2014). More recently next generation sequencing-based targeted panels have 9 
been developed to assess established and novel genes implicated in erythrocytosis 10 
(Camps, Petousi et al. 2016), negating the need for P50 testing. A targeted panel 11 
should be performed in patients in whom congenital erythrocytosis is suspected, 12 
particularly young patients or those with a family history.          13 
Diagnostic criteria for polycythaemia vera  14 
Presentation 15 
Polycythaemia vera (PV) presents at a median age of 60 years with a slight male 16 
predominance. Patients can present with arterial or venous vascular occlusive 17 
events, microvascular disturbances, or occasionally, haemorrhage. Splenic pain 18 
and/or enlargement, pruritus, gout and constitutional symptoms such as fatigue may 19 
be present. Alternatively, asymptomatic patients may be identified incidentally 20 
following a full blood count. All patients who are newly diagnosed with PV should be 21 
discussed in a multidisciplinary team setting.  22 
The recommended diagnostic criteria forJAK2-positive and the very rare JAK2-23 
negative PV are given in full in table I. 24 
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Role of the bone marrow biopsy in JAK2 V617F-positive patients 1 
Although the WHO classification considers histology to be useful in distinguishing PV 2 
from other myeloproliferative neoplasms (MPNs) (Arber, Orazi et al. 2016), several 3 
studies have reported high rates of non-consensus or failure to reach a histological 4 
diagnosis in patients with PV (Koopmans, Bot et al. 2011, Madelung, Bondo et al. 5 
2013) (Alvarez-Larrán, Ancochea et al. 2014) Given the uncertain utility of bone 6 
marrow histology in the diagnosis of uncomplicated PV, it is not mandatory in all 7 
patients, but should be considered if there are atypical features such as marked 8 
splenomegaly or a history of splanchnic vein thrombosis where it is necessary to 9 
establish if there is an occult myeloproliferative neoplasm. The degree of baseline 10 
fibrosis can also be ascertained, which as discussed below may have a prognostic 11 
role. Bone marrow biopsy may nonetheless be useful in those patients likely to have 12 
a long disease history, as a baseline sample for comparison in the event of 13 
suspected disease transformation. Abnormal karyotype and other molecular 14 
abnormalities (e.g. TET2 mutations) have been reported in PV and some may have 15 
prognostic value (Delic, Rose et al. 2016, Cerquozzi, Barraco et al. 2017) but these 16 
tests are not required routinely at diagnosis. 17 
Differentiation of JAK2 V617F-positive PV from other MPNs  18 
In patients with a JAK2 V617F mutation, haemoglobin and/or Hct are currently used 19 
as a surrogate for RCM to distinguish between PV and essential thrombocythaemia 20 
(ET) (Arber, Orazi et al. 2016), but Hct has the better accuracy in predicting red cell 21 
mass (Alvarez-Larrán, Pereira et al. 2012, Ancochea, Alvarez-Larrán et al. 2014).  22 
Concerns have however been raised that distinguishing PV from ET based on blood 23 
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count thresholds alone may fail to identify a subgroup of patients with “masked” PV, 1 
who may be better managed as PV rather than ET.   2 
The definition of masked PV has been inconsistent across studies.  When using a 3 
raised RCM to define an erythrocytosis, studies have shown that a Hct threshold of 4 
0.52 in males will fail to identify approximately 20% of male patients with a raised 5 
RCM, whilst the threshold of 0.48 in women is more sensitive (Alvarez-Larrán, 6 
Pereira et al. 2012). These ‘’masked’’ PV patients were reported to have similar 7 
outcomes to those with “overt” PV when managed equivalently (Alvarez-Larrán, 8 
Angona et al. 2016).  9 
By contrast, other studies have defined masked PV as those patients who did not 10 
meet the haemoglobin-based thresholds for PV but did meet the other WHO criteria, 11 
mainly bone marrow histology and JAK2 status. Patients meeting this definition had 12 
poorer outcomes in terms of myelofibrotic or leukaemic transformation and survival, 13 
but no difference in rate of thrombosis. Hct thresholds of 0.48/0.49 (females/males) 14 
were subsequently proposed to discriminate ET from PV in the WHO 2016 revision 15 
(Barosi, Tefferi et al. 2015).  16 
The proposed BSH Hct-based thresholds have good specificity but will miss a 17 
minority of patients with a raised RCM. By lowering the Hct threshold it may be 18 
possible to identify patients with histology more typical of PV who may have certain 19 
adverse outcomes, but these findings have not yet been reproduced independently. 20 
It is unknown whether management of any of these patients using a strict Hct target 21 
benefits their vascular risk. However, in patients with a JAK2 V617F mutation and 22 
borderline Hct levels (especially males with Hct 0.48-0.52), the possibility of true 23 
erythrocytosis should be considered, especially if the patient is at high risk of 24 
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vascular events. Options in this group include performing a RCM study to clarify the 1 
diagnosis or, pragmatically, managing the patient with a Hct target as for PV.  2 
It should also be noted that Hct is a poor surrogate of red cell mass in patients who 3 
have had splanchnic vein thrombosis (Lamy, Devillers et al. 1997), and these high-4 
risk patients are best managed with standard blood count targets regardless of blood 5 
count parameters at diagnosis. Hct is also reduced by pregnancy and gestation-6 
specific ranges should be used when considering the distinction between PV and ET 7 
in a patient presenting during pregnancy. 8 
 JAK2 V617F allele burden 9 
Quantitative assessments of the JAK2 V617F allele burden in peripheral blood 10 
granulocytes have shown that this parameter tends to be higher in PV than ET. A 11 
higher mutant allele burden correlates with certain clinical features at presentation 12 
including higher haemoglobin levels, higher WBCs, lower platelet counts, lower 13 
mean cell volume (MCV), lower serum ferritin and EPO, more splenomegaly and 14 
more pruritus (Dupont, Massé et al. 2007, Tefferi, Strand et al. 2007, Vannucchi, 15 
Antonioli et al. 2007, Passamonti, Rumi et al. 2010). However, there is no validated 16 
threshold at which JAK2 V617F allele burden can confirm or refute a diagnosis of PV 17 
and this investigation is not recommended routinely.   18 
Low level JAK2 V617F allele burden 19 
A low level JAK2 V617F mutation (allele burden <1-3%) should be interpreted in the 20 
context of clinical, haematological and other laboratory findings (Bench, White et al. 21 
2013). If the result is reproducible and does not represent a false positive, this 22 
finding may provide support for a diagnosis of a PV in a patient with otherwise 23 
unexplained, significant erythrocytosis (Perricone, Polverelli et al. 2017). However, 24 
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the JAK2 V617F mutation has been identified in normal individuals, often at a low 1 
allele burden, with a frequency that increases with age (Genovese, Kähler et al. 2 
2014, Jaiswal, Fontanillas et al. 2014). Caution is therefore warranted and 3 
comprehensive investigations should exclude an alternative secondary or congenital 4 
cause of erythrocytosis. The test should preferably be repeated within 3-6 months, 5 
and clinical assessment for other features of an MPN e.g. splenomegaly, bone 6 
marrow histological features, and screening for an additional mutation in JAK2 exon 7 
12 may be helpful. 8 
Recommendations:  9 
 In patients with persistent, significant and unexplained erythrocytosis, 10 
testing for JAK2 V617F is recommended, using a peripheral blood 11 
sample and an assay sufficiently sensitive to detect a mutant allele 12 
burden as low as 1-3%.  13 
(GRADE 1B) 14 
Risk stratification in PV 15 
The principal aims of risk stratification in PV are a) to select patients at higher risk of 16 
thrombosis for consideration of cytoreductive therapy and b) to provide the most 17 
accurate information to patients on the risks and implications of a diagnosis of PV. 18 
Thrombosis and Bleeding Risk 19 
At diagnosis, in the largest prospective study to date the European Collaboration on 20 
Low-Dose Aspirin in Polycythaemia Vera (ECLAP), age ≥ 65 years and a prior 21 
history of thrombosis were found to be the most important predictors of 22 
cardiovascular events (Marchioli, Finazzi et al. 2005). A baseline WBC of >15.0 × 23 
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109/l is a significant predictor of thrombosis, particularly an increased risk of 1 
myocardial infarction (Landolfi, Di Gennaro et al. 2007); however, prognostic models 2 
including leucocytosis have not been prospectively validated. Cardiovascular risk 3 
factors (smoking, diabetes mellitus, arterial hypertension, hypercholesterolaemia) 4 
also contribute to thrombotic risk in PV (Barbui, Vannucchi et al. 2017) (Landolfi, Di 5 
Gennaro et al. 2007) (Gangat, Strand et al. 2007). Once treatment is initiated, 6 
cardiovascular events occur more frequently in patients with less stringent Hct 7 
control (Marchioli, Finazzi et al. 2013) and when the WBC remains elevated >11 × 8 
109/l (Barbui, Masciulli et al. 2015). A relationship between thrombocytosis (either at 9 
diagnosis or follow-up) and thrombotic risk has not been established in PV (Di Nisio, 10 
Barbui et al. 2007), but extreme thrombocytosis (≥1500 × 109/l) is associated with 11 
increased risk of bleeding due to acquired von Willebrand disease and should be 12 
considered an indication for initiation of cytoreductive therapy (Budde and van 13 
Genderen 1997). 14 
Survival and Transformation Risk 15 
The impact of age, degree of leucocytosis and prior history of venous thrombosis on 16 
long term prognosis are well-established. In the ECLAP study, age >65 years was 17 
associated with inferior survival and age >70 years was associated with increased 18 
incidence of leukaemia/myelodysplasia (Marchioli, Finazzi et al. 2005). In the IWG-19 
MRT study, age>61 years was associated with inferior overall and leukaemia-free 20 
survival (Tefferi, Rumi et al. 2013). Longer disease duration has been associated 21 
with increased risk of myelofibrotic (MF) transformation (Marchioli, Finazzi et al. 22 
2005). Leucocytosis with WBC ≥15 × 109/l is associated with an inferior leukaemia-23 
free survival. A prior history of venous thrombosis also impacts negatively on overall 24 
survival. The IWG-MRT Prognostic Score uses these three parameters (age, WBC 25 
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and thrombotic history) to delineate distinct risk groups for overall survival (Tefferi, 1 
Rumi et al. 2013), but this prognostic score has not been independently validated in 2 
prospective studies. 3 
Several other clinical and laboratory variables have been reported to influence 4 
overall survival and/or risk of disease transformation. The presence of splenomegaly 5 
in PV patients has been associated with shorter overall survival and increased risk of 6 
transformation to both MF and AML (Abdulkarim, Ridell et al. 2011). The presence of 7 
an abnormal karyotype adversely impacts overall and leukaemia-free survival 8 
(Tefferi, Rumi et al. 2013). A raised lactate dehydrogenase (LDH) and the presence 9 
of reticulin fibrosis at diagnosis predict a higher rate of transformation to 10 
myelofibrosis (MF) but not to acute myeloid leukaemia (AML) (Alvarez-Larrán, 11 
Bellosillo et al. 2009) (Barbui, Thiele et al. 2012). Prospective analysis indicates that 12 
a JAK2 mutant allele burden of >50% is also associated with increased risk of MF 13 
(but not of AML or thrombosis) (Passamonti, Rumi et al. 2010) but the clinical utility 14 
of this measurement is not yet well-established. Although JAK2 exon12-mutated 15 
disease has a subtly different clinical phenotype to JAK2 V617F-driven PV (higher 16 
haemoglobin concentration, lower WBC), there appears to be no difference in long-17 
term prognosis (Passamonti, Elena et al. 2011). Targeted gene sequencing is a 18 
rapidly advancing area; approximately 15% of PV patients have mutations of ≥1 of 19 
ASXL1, SRSF2 and IDH2 and these patients have a reduced rate overall survival in 20 
univariate analysis (Tefferi, Lasho et al. 2016).    21 
Recommendations: Risk stratification 22 
 Age and thrombotic history should be used to define risk groups for 23 
thrombosis in PV (GRADE 1A).  24 
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 ‘High risk’: age ≥65 years and/or prior PV-associated arterial or venous 1 
thrombosis (GRADE1A) 2 
 ‘Low risk’: age <65 years and no PV-associated thrombotic history 3 
(GRADE 1A) 4 
  Some ‘low risk patients’ may be to be considered at higher risk in the 5 
presence of cardiovascular risk factors, elevated WBC, extreme 6 
thrombocytosis or Hct uncontrolled with venesection (GRADE 1B) 7 
 A number of variables including age, prior thrombosis, the presence of 8 
splenomegaly, serum LDH level, degree of reticulin staining, presence of 9 
an abnormal karyotype and JAK2 mutant allele burden may be utilised 10 
when counselling the patient on longer term prognosis including overall 11 
survival and disease transformation risk (GRADE 2B). 12 
 Deep sequencing for ‘high risk mutations’ e.g. ASXL1, SRSF2, IDH1/2 is 13 
not yet ‘standard of care’ but may be considered in selected cases 14 
where their presence may influence management. (GRADE 2B).  15 
Management of polycythaemia vera 16 
Patients with PV may present with thrombosis or cardiovascular disease. Disease-17 
related PV symptoms such as microvascular disturbance, pruritus (which may be 18 
excruciating), migraine-type headache and fatigue may also be presenting features 19 
which can significantly impact on quality of life (Harrison, Koschmieder et al. 2017). 20 
However, patients may be asymptomatic at presentation. 21 
The goals of treatment are to reduce complications and therefore improve survival. 22 
(Table III). Mortality is chiefly related to thromboembolic events and the principal aim 23 
of therapy is to reduce this risk. Targeted assessment and management of 24 
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cardiovascular risk factors such as hypertension, hypercholesterolaemia and 1 
diabetes mellitus and smoking is essential. Reduction in symptom burden is also a 2 
valid target for treatment. There is evidence that patients with inadequately 3 
controlled PV as determined by hydroxycarbamide (HC) use, splenomegaly and 4 
venesection requirements have a significantly higher symptom score measured by 5 
the MPN-SAF (Geyer, Scherber et al. 2016).  Frequent need for concurrent 6 
venesection may indicate need for dose alteration and or change of treatment. 7 
Haematocrit target 8 
The target for Hct control in PV was originally based on data from assessment of 9 
numbers of vascular events at different  Hct levels and it was estimated that a target 10 
below 0.45 should be maintained (Pearson and Wetherley-Mein 1978). This target 11 
has now been validated in a randomised clinical trial by the investigators of the 12 
CYTO-PV group who assessed the impact of stringent Hct reduction to <0.45 13 
compared with a more liberal target range of 0.45-0.50. Patients with a Hct target of 14 
< 0.45 had a significantly lower rate of cardiovascular death and major thrombosis 15 
than those with a target of 0.45-0.50 (Marchioli, Finazzi et al. 2013).  It was noted 16 
that the median WBC was significantly lower in the low Hct group, which may have 17 
been related to variation in the use of cytoreductive therapy between the groups. The 18 
impact of this parameter on the difference in outcome between the groups has been 19 
debated (McMullin, Harrison et al. 2013). 20 
The European LeukemiaNet (ELN) has by consensus recommended response 21 
criteria for PV . There is, however, little evidence that stringent achievement of these 22 
contributes to improved outcomes apart from the Hct target. These are a valuable 23 
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set of measures to assess treatment outcome with consistency across clinical trials 1 
but are not as useful in clinical practice (Barosi, Tefferi et al. 2015). 2 
Platelet and leucocyte target 3 
There is considerable published evidence that there is an association between 4 
increased WBC and thrombosis risk in PV (Barbui, Carobbio et al. 2009, 5 
Caramazza, Caracciolo et al. 2009) ((De Stefano, Za et al. 2010, Barbui, Masciulli et 6 
al. 2015) (Cerquozzi, Barraco et al. 2017). In contrast, one prospective study did not 7 
find such an association (Passamonti, Rumi et al. 2010). An analysis of long-term 8 
outcome of patients enrolled into the ECLAP study demonstrated that in patients 9 
with WBC >15 × 109/l there was increased incidence of thrombosis in comparison 10 
with those with WBC <10 × 109/l, largely related to an increase in myocardial 11 
infarction (Landolfi, Di Gennaro et al. 2007). In a retrospective study of PV to 12 
determine whether blood counts influenced the complication rate and survival, older 13 
age and elevated lactate dehydrogenase at diagnosis were found to be risk factors 14 
for vascular complications. When the vascular complication occurred, 41% of the 15 
patients with a complication had elevated WBC compared with 20% of patients 16 
without a complication (Enblom-Larsson, Girodon et al. 2017).The CYTO-PV study 17 
treatment arms which showed a lower thrombotic risk in those intensively managed 18 
to Hct <0.45 showed a comparatively lower WBC which may have contributed to the 19 
lower rate of thrombotic events (Marchioli, Finazzi et al. 2013) (McMullin, Harrison et 20 
al. 2013). There is no evidence from randomised trials to determine whether 21 
treatment targeted at reducing leucocyte count impacts on overall outcome and 22 
therefore no recommendation to target WBC as a treatment goal can be made. 23 
Indeed, no evidence for improved survival or lower thrombosis risk was seen in 24 
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patients achieving complete or partial response according to ELN criteria in an 1 
analysis of PV patients treated with HC whereas a better prognosis was seen when 2 
there was a white cell and platelet response (Alvarez-Larrán, Pereira et al. 2012). 3 
There is evidence that at extremes of platelet count there is a risk for bleeding and 4 
haemorrhage which may necessitate cytoreductive treatment in those with high 5 
counts. 6 
Allele burden reduction 7 
There is currently no indication to monitor allele burden sequentially outside the 8 
clinical trial setting. Whilst many studies have used allele burden reduction to assess 9 
impact of treatment there is currently no clear clinical impact of this as a target. Allele 10 
burden over 50% may correlate with progression to myelofibrosis (Passamonti, Rumi 11 
et al. 2010) but there is no evidence that this alters outcome and no evidence that 12 
lowering allele burden alters outcome. 13 
Bone marrow response 14 
There is no indication that serial monitoring of bone marrow morphology or fibrosis 15 
grade is of value but this should be undertaken if there is suspected progression 16 
from blood counts or symptomatology. 17 
Venesection 18 
Randomised trial data supports venesection of 200 – 500 mls blood at intervals 19 
suitable for patient size/tolerability should be used to achieve and maintain Hct of 20 
<0.45 (Marchioli, Finazzi et al. 2013). In low risk patients this is usually adequate to 21 
maintain target Hct. Where frequent venesection is needed to achieve this target 22 
then an alternative approach using a cytoreductive agent may need to be 23 
considered. High levels of venesection requirement have been reported to have an 24 
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association with higher thrombosis risk in patients on HC, specifically in those 1 
patients requiring 3 or more venesections per year (Alvarez-Larrán, Pérez-Encinas 2 
et al. 2017).  3 
No study has explicitly defined a gender difference in Hct target. A different target 4 
Hct in males and females is not recommended 5 
Iron deficiency may result from venesection. Whilst generally this is asymptomatic, 6 
restless legs, concentration problems, impaired cognitive function, dizziness, fatigue, 7 
headaches and inactivity and other symptoms may warrant a different treatment 8 
approach. Iron administration must be undertaken with extreme caution and with 9 
close supervision and monitoring of blood counts. Severe symptoms may warrant an 10 
alternative approach such as cytoreductive therapy. 11 
Aspirin 12 
The value of low-dose aspirin in patients with PV was demonstrated in the ECLAP 13 
study.  In this double blind, placebo-controlled randomised trial those randomised to 14 
aspirin 100 mg daily had significantly fewer vascular events at 3 years compared to 15 
placebo. There was a 60% decrease in the risk of the combined primary end-point 16 
which was of thrombotic events and death from cardiovascular causes. Major 17 
bleeding events were not significantly increased (Landolfi, Marchioli et al. 2004). 18 
Cytoreductive therapy 19 
High-risk patients should be considered for cytoreductive therapy. Low-risk patients 20 
who may benefit from cytoreduction include those with progressive splenomegaly, 21 
progressive leucocytosis (e.g. WBC >15 × 109/l) thrombocytosis (e.g. platelets >1500 22 
× 109/l) and poor tolerance of venesection. 23 
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Hydroxycarbamide 1 
Hydroxycarbamide is a cytoreductive agent, a non-alkylating antimetabolite which 2 
acts through inhibition of ribonucleotide reductase thereby regulating the rate of DNA 3 
synthesis. HC has a dose-dependent effect and needs to be individually titrated to 4 
achieve optimal count control. The efficacy of HC in controlling blood counts and 5 
preventing thrombosis has been extrapolated from the evidence in ET (Cortelazzo, 6 
Finazzi et al. 1995) and HC has been used in the management of PV. A recent 7 
retrospective study of PV demonstrated that patients treated with HC experienced 8 
significantly fewer vascular complications (11%) than patients treated with 9 
venesection only with a survival advantage for patients treated with HC when 10 
adjusted for variables supporting the use of this agent in first-line treatment (Enblom-11 
Larsson, Girodon et al. 2017). 12 
Side effects 13 
HC is generally well tolerated. Macrocytosis is expected. Myelosuppression is seen 14 
in some patients. Mucocutaneous side effects occur including ulceration in 15 
perimalleolar areas, oral aphthous ulceration, actinic keratosis, squamous cell 16 
cancer and other skin lesions. Gastrointestinal side effects have been reported.  17 
Leukaemogenic risk and risk of secondary malignancy 18 
There has been much debate and concern over the potential leukaemogenic risk of 19 
treatments used for PV and also the potential for secondary malignancies. The 20 
natural history of PV is that a proportion of patients will experience progression to 21 
acute leukaemia and myelofibrosis. There is currently no conclusive evidence that 22 
this risk is exacerbated by the use of HC alone. A recent large study European ET 23 
trial, the EXELS study compared anagrelide treated patient versus those treated with 24 
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other cytoreductive therapies and found there was a higher incidence of leukaemia 1 
and increased incidence of other cancers in those treated with other cytoreductive 2 
therapies including HC alone (Besses, Kiladjian et al. 2013) (Birgegård, Besses et al. 3 
2018).  A Swedish population-based study with a nationwide MPN cohort, identified 4 
those who developed AML/myelodysplastic (MDS) and matched controls, 5 
retrospective case record analysis was undertaken. Whilst the risk of AML/MDS was 6 
increased in patients exposed to high doses of 32P and alkylators or 2 or more 7 
cytoreductive agents, this was not seen in those patients treated exclusively with HC 8 
(Björkholm, Derolf et al. 2011). A long-term assessment from the ECLAP study 9 
showed no increased MDS/AML in those treated with HC alone (Finazzi, Caruso et 10 
al. 2005) and a retrospective analysis showed no association between HC or 11 
busulfan and AML (Tefferi, Rumi et al. 2013). 12 
A higher incidence of second malignancies has been seen in a small cohort of  13 
patients treated with HC compared to interferon (INF) alone (Hansen, Sørensen et 14 
al. 2017), particularly non-melanoma skin cancers, and this has been seen in 15 
population-based studies with increased risk of  non-melanotic skin cancer in 16 
patients treated with HC, especially in older patients of male sex (Gómez, Guillem et 17 
al. 2016).  Another study looked at treatment characteristics of a large number of 18 
patients with ET, diagnosed and followed during a 30-year period. The different 19 
therapies administered, comprising HC and alkylating agents, did not appear to have 20 
any impact on the development of secondary malignancy with a similar rate of 21 
secondary malignancies in untreated patients. Male gender and age >60 years were 22 
the only factors that were correlated with higher risk (Santoro, Sperduti et al. 2017). 23 
HC is recommended as a first line cytoreductive treatment option for all patients for 24 
whom this is required. The risk benefit profiles need to be discussed with patients. 25 
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HC is not safe in pregnancy and it is recommended that it be stopped 3 months prior 1 
to intended conception. Adequate contraception should be used by patients 2 
receiving this medication. 3 
Hydroxycarbamide intolerance and resistance 4 
There has been an attempt to define the criteria to suggest failure of HC as first line 5 
therapy for PV. The ELN have by consensus suggested a unified definition of 6 
resistance to intolerance or hydroxycarbamide. This classification identifies a group 7 
of patients who have a poorer prognosis who may require or benefit from a change 8 
of treatment (Barosi, Birgegard et al. 2010) (Table IV). In retrospective studies 9 
resistance is associated with worse survival, with development of anaemia or 10 
cytopenias identifying a group with poorer outcome (Alvarez-Larrán, Pereira et al. 11 
2012, Alvarez-Larrán, Pérez-Encinas et al. 2017). 12 
Interferons 13 
Numerous single centre studies have observed that interferon-α (IFN-α) can be 14 
successfully to normalise blood counts, reduce splenomegaly and prevent 15 
thrombosis in PV (Silver 2006) It is also effective in many patients in reducing 16 
pruritus (Taylor, Dolan et al. 1996). This agent is of particular interest due to its anti-17 
clonal activity as demonstrated by molecular (as assessed by mutation burden of 18 
JAK2 V617F) and histological remissions (Larsen, Møller et al. 2009) (Stauffer 19 
Larsen, Iversen et al. 2013). No leukaemogenic effect has been identified. However, 20 
side effects often limit use and most commonly include flu-like symptoms and mood 21 
changes. In a minority of patients, endocrine and autoimmune disorders also occur 22 
warranting regular monitoring of thyroid function and additional investigations where 23 
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indicated. Treatment with IFN-α is usually continuous but occasionally it can be 1 
stopped for prolonged periods of time.  2 
Longer acting pegylated IFN-α-2a (PEG-α-2a) requires less frequent administration 3 
and is generally better tolerated. Two Phase II studies of PEG-α-2a demonstrated 4 
complete responses of 70-95% as well as complete molecular remissions of 14 – 5 
24%  with treatment discontinuation due to side-effects observed in 8-10% of 6 
patients only (Kiladjian, Cassinat et al. 2006) (Quintás-Cardama, Kantarjian et al. 7 
2009) Comparable results have been noted in single-centre studies (Crisà, Cerrano 8 
et al. 2017, Gowin, Jain et al. 2017) A Phase III study of PEG-α-2a versus HC as 9 
first-line treatment for high-risk PV is underway and interim analysis shows no 10 
significant advantage  for PEG-α-2a over HC (Mascarenhas, Prchal et al. 2016 11 
 ) 12 
Pegylated interferon-α-2b (PEG-α-2b) has also been assessed in two studies which 13 
included PV patients and whilst it has been shown to be effective in controlling 14 
disease, clinical use has been limited by high discontinuation rates due to side 15 
effects (Samuelsson, Hasselbalch et al. 2006) (Jabbour, Kantarjian et al. 2007). 16 
Recently, interim analysis from a phase III study of proline-PEG-α-2b 17 
(Ropeginterferon) has demonstrated complete haematological responses in 71% of 18 
PV patients, sustained reductions in mutation burden of JAK2 V617F, good 19 
tolerability and confirmed non-inferiority (or no significant advantage) to HC as first 20 
line treatment for patients with high risk PV (Gisslinger, Klade et al. 2017)  21 
Ruxolitinib 22 
 Following early studies of the JAK1 and 2 inhibitor ruxolitinib in MF this agent was 23 
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tested in PV and ET, in patients resistant or intolerant to HC. The majority of PV 1 
patients became phlebotomy-independent and had an improvement in symptoms 2 
and splenomegaly (>50%) (Verstovsek, Passamonti et al. 2014).  3 
Following this a phase III trial RESPONSE evaluated the efficacy and safety of 4 
ruxolitinib in a specific subgroup of PV patients who were both refractory to, or 5 
intolerant of HC and who required ongoing phlebotomy and had splenomegaly 6 
(Vannucchi 2015). Patients were randomized between ruxolitinib and best available 7 
therapy (BAT), which could include any therapy, and crossover was permitted. 8 
Patients on ruxolitinib achieved good Hct control and spleen response, although only 9 
21% of patients achieved both. Improvements in disease-related symptoms were 10 
described. Anaemia and thrombocytopenia were the main haematological adverse 11 
events. Herpes zoster infection was described in patients on ruxolitinib. Non-12 
melanoma skin cancer was reported in both arms.  Thromboembolic events were 13 
more frequent on BAT arm but this was not a pre-determined outcome. Data 14 
published from this study also suggested that molecular responses can occur 15 
perhaps to the same extent as with interferon (Pieri, Pancrazzi et al. 2015, 16 
Vannucchi, Verstovsek et al. 2017) and that even profoundly iron deficient patients 17 
can normalise their iron parameters with ruxolitinib therapy (Verstovsek, Harrison et 18 
al. 2017). Disease transformation occurred and there is no information to suggest 19 
that ruxolitinib therapy impacts these events. 20 
However, the RESPONSE study had some inherent bias: first, the population of the 21 
study is highly selected as they had to be venesection-dependent. Second, patients 22 
on the BAT arm were allowed to receive HC and many did so reflecting the lack of 23 
therapy options in this setting. Finally, as patients received other treatments before 24 
ruxolitinib and crossed between the treatment arms it is difficult to establish if the 25 
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events such as skin cancer, or disease transformation could be an effect of the 1 
ruxolitinib or occur as an accumulative effect of other cytoreductive therapies.  2 
Following RESPONSE, a second randomized open label phase 3b study 3 
(RESPONSE-2) was developed to determinate the efficacy of ruxolitinib versus BAT 4 
in a similar population of PV patients as RESPONSE but the patients were not 5 
required to have splenomegaly (Passamonti, Griesshammer et al. 2017).  Here 6 
ruxolitinib showed good responses in controlling Hct and PV-related symptoms. 7 
However, the follow-up for the study is short, the majority of patients had received 8 
HC previously and HC was part of BAT options. 9 
RELIEF was a randomized study focusing on PV-related symptoms for patients on a 10 
stable dose of HC (Mesa, Vannucchi et al. 2017) with crossover to ruxolitinib allowed 11 
after week 16. The primary endpoint, the percentage of patients with ≥50% reduction 12 
in symptoms, was seen in significantly more patients in the ruxolitinib arm. A 13 
statistically significant reduction in itching was also noted in the ruxolitinib. This study 14 
was perhaps underpowered but showed that ruxolitinib improves symptoms in 15 
patients with controlled PV. 16 
The evidence from these trials suggests ruxolitinib has a role in the treatment of HC-17 
resistant or intolerant PV. 18 
Other treatments 19 
There are several cytotoxic agents that are effective in controlling blood counts but 20 
which have been associated with increased rates of leukaemic transformation. 21 
Busulfan, a cell cycle non-specific alkylating agent, has such an association. 22 
However, retrospective studies show that it is an effective therapy for MPNs (Begna, 23 
Abdelatif et al. 2016) although an actuarial probability of leukaemia transformation of 24 
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10% at 3 years was reported in one study (Alvarez-Larrán, Martínez-Avilés et al. 1 
2014). Busulfan is useful in treating PV in those with limited life expectancy. It can be 2 
given in dosing regimens of 2 – 4 mg daily until counts are controlled but patients 3 
need to be seen frequently to check for neutropenia or thrombocytopenia so that 4 
treatment can be interrupted. An alternative regimen is pulsed single 25 – 50 mg 5 
doses at intervals of approximately 6 weeks. 6 
32P is has a leukaemogenic potential but a single intravenous dose can be effective 7 
for long term control. One retrospective study showed its efficacy with remission 8 
rates of 90% (Lawless, McMullin et al. 2016). Doses can be repeated if the response 9 
is lost but the leukaemogenic risk increases with the cumulative exposure. 32P is a 10 
suitable treatment for those with limited life expectancy who are self-caring (so that 11 
there is no risk for carers). 12 
Pipobroman a bromide derivative of piperazine similar to alkylating agents has been 13 
compared to HC in randomised trials and shown to be effective but has continuing 14 
leukaemogenic potential (Kiladjian, Chevret et al. 2011) and therefore should only be 15 
used in those with limited life expectancy. 16 
Anagrelide, a megakaryocyte differentiation inhibitor, is licensed as second line 17 
therapy in ET. Retrospective reports of anagrelide used in combination with HC in 18 
PV have shown that it is effective at lowering the platelet count and it may be useful 19 
in combination when an elevated platelet count is an issue (Ahn, Natelson et al. 20 
2013). 21 
A number of other agents have been used for cytoreduction in PV with varying 22 
efficacy. A small study investigated the use of imatinib. The complete response rate 23 
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was 30% with frequent side effects. This has not been studied further and is not 1 
recommended for the treatment of PV (Silver, Bourla et al. 2012) 2 
Histone-deacetylase inhibitors (HDACi) inhibit proliferation of cells with a JAK2 3 
V617F mutation. Two HDACis have been tested in PV in phase 2 trials. Vorinostat in 4 
a trial of PV and ET achieved a response rate of 35% but with a very high drop-out 5 
rate because of adverse events (Andersen, McMullin et al. 2013). Givinostat was 6 
assessed in a phase 2 study of PV unresponsive to HC monotherapy with response 7 
rates in the order of 50% and with high rates of improvement in pruritus (Finazzi, 8 
Vannucchi et al. 2013). HDACis need to be assessed further in trials before they can 9 
be recommended for clinical use. 10 
 11 
Following evaluation of all recent evidence it is recommended that all patients 12 
including those stratified as low-risk should be venesected to a Hct target of 0.45 and 13 
given low dose aspirin if there are no specific contraindications. High-risk patients 14 
should be treated with cytoreductive therapy in addition. However, low-risk patients 15 
with any of the criteria listed below, may also need to be considered for cytoreductive 16 
therapy 17 
 18 
RECOMMENDATIONS: Management options for ALL PV including low-risk 19 
patients 20 
 Target haematocrit of <0.45 in all patients (GRADE 1A) 21 
 Low dose aspirin (75 – 100 mg) in all patients (GRADE 1A) 22 
 Targeted intervention to reduce cardiovascular risk factors 23 
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Consider cytoreductive therapy in low-risk patients with:  1 
 History of treated arterial hypertension, ischaemia heart disease or 2 
diabetes mellitus 3 
 Persistent leucocytosis (e.g. WBC >15 × 109/l)  4 
 Uncontrolled haematocrit (or poor tolerability of venesection) 5 
 Extreme / progressive thrombocytosis (e.g. > 1500 × 109/l) and/or 6 
haemorrhagic symptoms 7 
 Progressive / symptomatic splenomegaly 8 
 Uncontrolled or progressive disease-related symptoms e.g. weight loss, 9 
sweats 10 
 (GRADE 1B) 11 
Recommendations: Management options in high-risk patients 12 
 First Line: hydroxycarbamide or interferon (preferably pegylated 13 
interferon) 14 
 Second line: In patients treated with hydroxycarbamide 1st line 15 
interferon as second line treatment or where treated with interferon 1st 16 
line recommend hydroxycarbamide as second line treatment  17 
 Consider pegylated interferon as second line in those patients who have 18 
had non-pegylated interferon 1st line and could not tolerate it 19 
  Ruxolitinib 2nd /3rd line in HC resistant or intolerant  20 
(GRADE 1A) 21 
Third-line or further treatment options 22 
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 Busulfan or 32P or pipobroman in those with limited life expectancy 1 
(GRADE 1B). 2 
 Anagrelide in combination with hydroxycarbamide may be helpful in 3 
those where platelet control is difficult (GRADE 2C) 4 
Acknowledgements 5 
The authors would like to the BSH task forces and the BSH sounding boards for their 6 
support in preparing this guideline. They also wish to thank Jacky Wilson for help in 7 
undertaking the initial literature review. All authors reviewed the literature search, 8 
formulated and agreed guidance and contributed to drafting writing and editing of the 9 
manuscript. 10 
Declaration of Interest 11 
The BSH paid the expenses incurred during the writing of this guidance. All authors 12 
have made a declaration of interests to the BSH and Task Force Chairs which may 13 
be reviewed on request. 14 
References 15 
Abdulkarim, K., B. Ridell, P. Johansson, J. Kutti, S. Safai-Kutti and B. Andréasson (2011). "The impact 16 
of peripheral blood values and bone marrow findings on prognosis for patients with essential 17 
thrombocythemia and polycythemia vera." Eur J Haematol 86(2): 148-155. 18 
Ahn, I. E., E. Natelson and L. Rice (2013). "Successful long-term treatment of Philadelphia 19 
chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and 20 
anagrelide." Clin Lymphoma Myeloma Leuk 13 Suppl 2: S300-304. 21 
Alvarez-Larrán, A., A. Ancochea, M. García, F. Climent, F. García-Pallarols, A. Angona, A. Senín, C. 22 
Barranco, L. Martínez-Avilés, S. Serrano, B. Bellosillo and C. Besses (2014). "WHO-histological criteria 23 
for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene 24 
mutations and clinical outcomes." Br J Haematol 166(6): 911-919. 25 
Alvarez-Larrán, A., A. Angona, A. Ancochea, F. García-Pallarols, C. Fernández, R. Longarón, B. 26 
Bellosillo and C. Besses (2016). "Masked polycythaemia vera: presenting features, response to 27 
treatment and clinical outcomes." Eur J Haematol 96(1): 83-89. 28 
Alvarez-Larrán, A., B. Bellosillo, L. Martínez-Avilés, S. Saumell, A. Salar, E. Abella, E. Gimeno, S. 29 
Serrano, L. Florensa, B. Sánchez, C. Pedro and C. Besses (2009). "Postpolycythaemic myelofibrosis: 30 
frequency and risk factors for this complication in 116 patients." Br J Haematol 146(5): 504-509. 31 
32 
 
Alvarez-Larrán, A., L. Martínez-Avilés, J. C. Hernández-Boluda, F. Ferrer-Marín, M. L. Antelo, C. 1 
Burgaleta, M. I. Mata, B. Xicoy, A. Martínez-Trillos, M. T. Gómez-Casares, M. A. Durán, B. Marcote, A. 2 
Ancochea, A. Senín, A. Angona, M. Gómez, V. Vicente, F. Cervantes, B. Bellosillo and C. Besses 3 
(2014). "Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or 4 
intolerant to hydroxyurea." Ann Hematol 93(12): 2037-2043. 5 
Alvarez-Larrán, A., A. Pereira, F. Cervantes, E. Arellano-Rodrigo, J. C. Hernández-Boluda, F. Ferrer-6 
Marín, A. Angona, M. Gómez, B. Muiña, H. Guillén, A. Teruel, B. Bellosillo, C. Burgaleta, V. Vicente 7 
and C. Besses (2012). "Assessment and prognostic value of the European LeukemiaNet criteria for 8 
clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera." 9 
Blood 119(6): 1363-1369. 10 
Alvarez-Larrán, A., M. Pérez-Encinas, F. Ferrer-Marín, J. C. Hernández-Boluda, M. J. Ramírez, J. 11 
Martínez-López, E. Magro, Y. Cruz, M. I. Mata, P. Aragües, M. L. Fox, B. Cuevas, S. Montesdeoca, J. A. 12 
Hernández-Rivas, V. García-Gutiérrez, M. T. Gómez-Casares, J. L. Steegmann, M. A. Durán, M. 13 
Gómez, A. Kerguelen, A. Bárez, M. C. García, C. Boqué, J. M. Raya, C. Martínez, M. Albors, F. García, 14 
C. Burgaleta, C. Besses and G. E. d. N. M. F. Negativas (2017). "Risk of thrombosis according to need 15 
of phlebotomies in patients with polycythemia vera treated with hydroxyurea." Haematologica 16 
102(1): 103-109. 17 
Ancochea, A., A. Alvarez-Larrán, C. Morales-Indiano, F. García-Pallarols, L. Martínez-Avilés, A. 18 
Angona, A. Senín, B. Bellosillo and C. Besses (2014). "The role of serum erythropoietin level and JAK2 19 
V617F allele burden in the diagnosis of polycythaemia vera." Br J Haematol 167(3): 411-417. 20 
Andersen, C. L., M. F. McMullin, E. Ejerblad, S. Zweegman, C. Harrison, S. Fernandes, D. Bareford, S. 21 
Knapper, J. Samuelsson, E. Löfvenberg, O. Linder, B. Andreasson, E. Ahlstrand, M. K. Jensen, O. W. 22 
Bjerrum, H. Vestergaard, H. Larsen, T. W. Klausen, T. Mourits-Andersen and H. C. Hasselbalch (2013). 23 
"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential 24 
thrombocythaemia." Br J Haematol 162(4): 498-508. 25 
Arber, D. A., A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz, M. M. Le Beau, C. D. Bloomfield, M. 26 
Cazzola and J. W. Vardiman (2016). "The 2016 revision to the World Health Organization 27 
classification of myeloid neoplasms and acute leukemia." Blood 127(20): 2391-2405. 28 
Barbui, T., A. Carobbio, A. Rambaldi and G. Finazzi (2009). "Perspectives on thrombosis in essential 29 
thrombocythemia and polycythemia vera: is leukocytosis a causative factor?" Blood 114(4): 759-763. 30 
Barbui, T., A. Masciulli, M. R. Marfisi, G. Tognoni, G. Finazzi, A. Rambaldi and A. Vannucchi (2015). 31 
"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study." 32 
Blood 126(4): 560-561. 33 
Barbui, T., J. Thiele, F. Passamonti, E. Rumi, E. Boveri, M. L. Randi, I. Bertozzi, F. Marino, A. M. 34 
Vannucchi, L. Pieri, G. Rotunno, H. Gisslinger, B. Gisslinger, L. Müllauer, G. Finazzi, A. Carobbio, A. 35 
Gianatti, M. Ruggeri, I. Nichele, E. D'Amore, A. Rambaldi and A. Tefferi (2012). "Initial bone marrow 36 
reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome." Blood 119(10): 2239-37 
2241. 38 
Barbui, T., A. M. Vannucchi, A. Carobbio, E. Rumi, G. Finazzi, H. Gisslinger, M. Ruggeri, M. L. Randi, 39 
M. Cazzola, A. Rambaldi, B. Gisslinger, L. Pieri, J. Thiele, A. Pardanani and A. Tefferi (2017). "The 40 
effect of arterial hypertension on thrombosis in low-risk polycythemia vera." Am J Hematol 92(1): 41 
E5-E6. 42 
Barosi, G., G. Birgegard, G. Finazzi, M. Griesshammer, C. Harrison, H. Hasselbalch, J. J. Kiladijan, E. 43 
Lengfelder, R. Mesa, M. F. Mc Mullin, F. Passamonti, J. T. Reilly, A. M. Vannucchi and T. Barbui 44 
(2010). "A unified definition of clinical resistance and intolerance to hydroxycarbamide in 45 
polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus 46 
process." Br J Haematol 148(6): 961-963. 47 
Barosi, G., A. Tefferi, C. Besses, G. Birgegard, F. Cervantes, G. Finazzi, H. Gisslinger, M. 48 
Griesshammer, C. Harrison, R. Hehlmann, S. Hermouet, J. J. Kiladjian, N. Kröger, R. Mesa, M. F. Mc 49 
Mullin, A. Pardanani, F. Passamonti, J. Samuelsson, A. M. Vannucchi, A. Reiter, R. T. Silver, S. 50 
Verstovsek, G. Tognoni and T. Barbui (2015). "Clinical end points for drug treatment trials in BCR-51 
33 
 
ABL1-negative classic myeloproliferative neoplasms: consensus statements from European 1 
LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and 2 
Treatment (IWG-MRT)." Leukemia 29(1): 20-26. 3 
Begna, K., A. Abdelatif, S. Schwager, C. Hanson, A. Pardanani and A. Tefferi (2016). "Busulfan for the 4 
treatment of myeloproliferative neoplasms: the Mayo Clinic experience." Blood Cancer J 6: e427. 5 
Bench, A. J., H. E. White, L. Foroni, A. L. Godfrey, G. Gerrard, S. Akiki, A. Awan, I. Carter, A. Goday-6 
Fernandez, S. E. Langabeer, T. Clench, J. Clark, P. A. Evans, D. Grimwade, A. Schuh, M. F. McMullin, A. 7 
R. Green, C. N. Harrison, N. C. Cross and B. C. f. S. i. Haematology (2013). "Molecular diagnosis of the 8 
myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant 9 
mutations." Br J Haematol 160(1): 25-34. 10 
Bento, C., M. J. Percy, B. Gardie, T. M. Maia, R. van Wijk, S. Perrotta, F. Della Ragione, H. Almeida, C. 11 
Rossi, F. Girodon, M. Aström, D. Neumann, S. Schnittger, B. Landin, M. Minkov, M. L. Randi, S. 12 
Richard, N. Casadevall, W. Vainchenker, S. Rives, S. Hermouet, M. L. Ribeiro, M. F. McMullin, H. 13 
Cario, A. Chauveau, A. P. Gimenez-Roqueplo, B. Bressac-de-Paillerets, D. Altindirek, F. Lorenzo, F. 14 
Lambert, H. Dan, S. Gad-Lapiteau, A. Catarina Oliveira, C. Fraga, G. Taradin, G. Martin-Nuñez, H. 15 
Vitória, H. Diaz Aguado, J. Palmblad, J. Vidán, L. Relvas, M. Luigi Larocca, M. Luigia Randi, M. Pedro 16 
Silveira, M. Percy, M. Gross, R. Marques da Costa, S. Beshara, T. Ben-Ami, V. Ugo and ECE-17 
Consortium (2014). "Genetic basis of congenital erythrocytosis: mutation update and online 18 
databases." Hum Mutat 35(1): 15-26. 19 
Berlin, N. I. (1975). "Diagnosis and classification of the polycythemias." Semin Hematol 12(4): 339-20 
351. 21 
Besses, C., J. J. Kiladjian, M. Griesshammer, L. Gugliotta, C. Harrison, R. Coll, J. Smith, B. Abhyankar 22 
and G. Birgegård (2013). "Cytoreductive treatment patterns for essential thrombocythemia in 23 
Europe. Analysis of 3643 patients in the EXELS study." Leuk Res 37(2): 162-168. 24 
Birgegård, G., C. Besses, M. Griesshammer, L. Gugliotta, C. N. Harrison, M. Hamdani, J. Wu, H. 25 
Achenbach and J. J. Kiladjian (2018). "Treatment of essential thrombocythemia in Europe: a 26 
prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide 27 
Efficacy and Long-term Safety study." Haematologica 103(1): 51-60. 28 
Björkholm, M., A. R. Derolf, M. Hultcrantz, S. Y. Kristinsson, C. Ekstrand, L. R. Goldin, B. Andreasson, 29 
G. Birgegård, O. Linder, C. Malm, B. Markevärn, L. Nilsson, J. Samuelsson, F. Granath and O. 30 
Landgren (2011). "Treatment-related risk factors for transformation to acute myeloid leukemia and 31 
myelodysplastic syndromes in myeloproliferative neoplasms." J Clin Oncol 29(17): 2410-2415. 32 
Budde, U. and P. J. van Genderen (1997). "Acquired von Willebrand disease in patients with high 33 
platelet counts." Semin Thromb Hemost 23(5): 425-431. 34 
Camps, C., N. Petousi, C. Bento, H. Cario, R. R. Copley, M. F. McMullin, R. van Wijk, P. J. Ratcliffe, P. 35 
A. Robbins, J. C. Taylor and W. Consortium (2016). "Gene panel sequencing improves the diagnostic 36 
work-up of patients with idiopathic erythrocytosis and identifies new mutations." Haematologica 37 
101(11): 1306-1318. 38 
Caramazza, D., C. Caracciolo, R. Barone, A. Malato, G. Saccullo, V. Cigna, S. Berretta, L. Schinocca, G. 39 
Quintini, V. Abbadessa, F. Di Raimondo and S. Siragusa (2009). "Correlation between leukocytosis 40 
and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms." Ann Hematol 41 
88(10): 967-971. 42 
Castleden, C. M. and P. V. Cole (1975). "Carboxyhaemoglobin levels of smokers and non-smokers 43 
working in the City of London." Br J Ind Med 32(2): 115-118. 44 
Cerquozzi, S., D. Barraco, T. Lasho, C. Finke, C. A. Hanson, R. P. Ketterling, A. Pardanani, N. Gangat 45 
and A. Tefferi (2017). "Risk factors for arterial versus venous thrombosis in polycythemia vera: a 46 
single center experience in 587 patients." Blood Cancer J 7(12): 662. 47 
Cortelazzo, S., G. Finazzi, M. Ruggeri, O. Vestri, M. Galli, F. Rodeghiero and T. Barbui (1995). 48 
"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis." N Engl J 49 
Med 332(17): 1132-1136. 50 
34 
 
Crisà, E., M. Cerrano, E. Beggiato, G. Benevolo, G. Lanzarone, P. M. Manzini, A. Borchiellini, L. Riera, 1 
M. Boccadoro and D. Ferrero (2017). "Can pegylated interferon improve the outcome of 2 
polycythemia vera patients?" J Hematol Oncol 10(1): 15. 3 
De Stefano, V., T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Micò, A. Tieghi, R. R. Cacciola, C. 4 
Santoro, G. Gerli, P. Guglielmelli, L. Pieri, F. Scognamiglio, F. Rodeghiero, E. M. Pogliani, G. Finazzi, L. 5 
Gugliotta, G. Leone, T. Barbui and G. C. M. N. W. Party (2010). "Leukocytosis is a risk factor for 6 
recurrent arterial thrombosis in young patients with polycythemia vera and essential 7 
thrombocythemia." Am J Hematol 85(2): 97-100. 8 
Delic, S., D. Rose, W. Kern, N. Nadarajah, C. Haferlach, T. Haferlach and M. Meggendorfer (2016). 9 
"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct 10 
mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera." 11 
Br J Haematol 175(3): 419-426. 12 
Di Nisio, M., T. Barbui, L. Di Gennaro, G. Borrelli, G. Finazzi, R. Landolfi, G. Leone, R. Marfisi, E. 13 
Porreca, M. Ruggeri, A. W. Rutjes, G. Tognoni, A. M. Vannucchi, R. Marchioli and E. C. o. L.-d. A. i. P. 14 
V. E. Investigators (2007). "The haematocrit and platelet target in polycythemia vera." Br J Haematol 15 
136(2): 249-259. 16 
Dupont, S., A. Massé, C. James, I. Teyssandier, Y. Lécluse, F. Larbret, V. Ugo, P. Saulnier, S. Koscielny, 17 
J. P. Le Couédic, N. Casadevall, W. Vainchenker and F. Delhommeau (2007). "The JAK2 617V>F 18 
mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary 19 
cells from patients with polycythemia vera." Blood 110(3): 1013-1021. 20 
Enblom-Larsson, A., F. Girodon, M. Bak, D. Hersby, V. Jooste, H. Hasselbalch, P. Johansson and B. 21 
Andreasson (2017). "A retrospective analysis of the impact of treatments and blood counts on 22 
survival and the risk of vascular events during the course of polycythaemia vera." Br J Haematol 23 
177(5): 800-805. 24 
Finazzi, G., V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli, L. Gugliotta, R. Landolfi, J. Kutti, H. 25 
Gisslinger, R. Marilus, C. Patrono, E. M. Pogliani, M. L. Randi, A. Villegas, G. Tognoni, T. Barbui and E. 26 
Investigators (2005). "Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a 27 
prospective observational study." Blood 105(7): 2664-2670. 28 
Finazzi, G., A. M. Vannucchi, V. Martinelli, M. Ruggeri, F. Nobile, G. Specchia, E. M. Pogliani, O. M. 29 
Olimpieri, G. Fioritoni, C. Musolino, D. Cilloni, P. Sivera, G. Barosi, M. C. Finazzi, S. Di Tollo, T. 30 
Demuth, T. Barbui and A. Rambaldi (2013). "A phase II study of Givinostat in combination with 31 
hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide 32 
monotherapy." Br J Haematol 161(5): 688-694. 33 
Gangat, N., J. Strand, C. Y. Li, W. Wu, A. Pardanani and A. Tefferi (2007). "Leucocytosis in 34 
polycythaemia vera predicts both inferior survival and leukaemic transformation." Br J Haematol 35 
138(3): 354-358. 36 
Genovese, G., A. K. Kähler, R. E. Handsaker, J. Lindberg, S. A. Rose, S. F. Bakhoum, K. Chambert, E. 37 
Mick, B. M. Neale, M. Fromer, S. M. Purcell, O. Svantesson, M. Landén, M. Höglund, S. Lehmann, S. 38 
B. Gabriel, J. L. Moran, E. S. Lander, P. F. Sullivan, P. Sklar, H. Grönberg, C. M. Hultman and S. A. 39 
McCarroll (2014). "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence." 40 
N Engl J Med 371(26): 2477-2487. 41 
Geyer, H., R. Scherber, H. Kosiorek, A. C. Dueck, J. J. Kiladjian, Z. Xiao, S. Slot, S. Zweegman, F. 42 
Sackmann, A. K. Fuentes, D. Hernández-Maraver, K. Döhner, C. N. Harrison, D. Radia, P. Muxi, C. 43 
Besses, F. Cervantes, P. L. Johansson, B. Andreasson, A. Rambaldi, T. Barbui, K. Bonatz, A. Reiter, F. 44 
Boyer, G. Etienne, J. C. Ianotto, D. Ranta, L. Roy, J. Y. Cahn, N. Maldonado, G. Barosi, M. L. Ferrari, R. 45 
P. Gale, G. Birgegard, Z. Xu, Y. Zhang, X. Sun, J. Xu, P. Zhang, P. A. te Boekhorst, S. Commandeur, H. 46 
Schouten, H. L. Pahl, M. Griesshammer, F. Stegelmann, T. Lehmann, Z. Senyak, A. M. Vannucchi, F. 47 
Passamonti, J. Samuelsson and R. A. Mesa (2016). "Symptomatic Profiles of Patients With 48 
Polycythemia Vera: Implications of Inadequately Controlled Disease." J Clin Oncol 34(2): 151-159. 49 
Gisslinger, H., C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva, M. Egyed, V. Rossiev, P. Dulicek, 50 
A. Illes, H. Pylypenko, L. Sicheva, J. Mayer, V. Yablokova, K. Krejcy, B. Grohman-Izay, H. Hasselbalch, 51 
35 
 
R. Kralovica and J. Kiladjian (2017). Ropeginterferon alfa-2b induces high rates of clinical, 1 
hematological and molecular responses in polycythemia vera: Two-year results from the first 2 
prospective randomized controlled trial. Blood. 130: 320. 3 
Gowin, K., T. Jain, H. Kosiorek, R. Tibes, J. Camoriano, J. Palmer and R. Mesa (2017). "Pegylated 4 
interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients 5 
treated off clinical trial." Leuk Res 54: 73-77. 6 
Gómez, M., V. Guillem, A. Pereira, F. Ferrer-Marín, A. Álvarez-Larrán, A. Kerguelen, N. Estrada, J. 7 
Martínez-López, A. Angona, P. Amat, B. Navarro, C. Besses and J. C. Hernández-Boluda (2016). "Risk 8 
factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia 9 
vera." Eur J Haematol 96(3): 285-290. 10 
Hansen, I. O., A. L. Sørensen and H. C. Hasselbalch (2017). "Second malignancies in hydroxyurea and 11 
interferon-treated Philadelphia-negative myeloproliferative neoplasms." Eur J Haematol 98(1): 75-12 
84. 13 
Harrison, C. N., S. Koschmieder, L. Foltz, P. Guglielmelli, T. Flindt, M. Koehler, J. Mathias, N. Komatsu, 14 
R. N. Boothroyd, A. Spierer, J. Perez Ronco, G. Taylor-Stokes, J. Waller and R. A. Mesa (2017). "The 15 
impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results 16 
from the international MPN Landmark survey." Ann Hematol 96(10): 1653-1665. 17 
Jabbour, E., H. Kantarjian, J. Cortes, D. Thomas, G. Garcia-Manero, A. Ferrajoli, S. Faderl, M. A. Richie, 18 
M. Beran, F. Giles and S. Verstovsek (2007). "PEG-IFN-alpha-2b therapy in BCR-ABL-negative 19 
myeloproliferative disorders: final result of a phase 2 study." Cancer 110(9): 2012-2018. 20 
Jaiswal, S., P. Fontanillas, J. Flannick, A. Manning, P. V. Grauman, B. G. Mar, R. C. Lindsley, C. H. 21 
Mermel, N. Burtt, A. Chavez, J. M. Higgins, V. Moltchanov, F. C. Kuo, M. J. Kluk, B. Henderson, L. 22 
Kinnunen, H. A. Koistinen, C. Ladenvall, G. Getz, A. Correa, B. F. Banahan, S. Gabriel, S. Kathiresan, H. 23 
M. Stringham, M. I. McCarthy, M. Boehnke, J. Tuomilehto, C. Haiman, L. Groop, G. Atzmon, J. G. 24 
Wilson, D. Neuberg, D. Altshuler and B. L. Ebert (2014). "Age-related clonal hematopoiesis 25 
associated with adverse outcomes." N Engl J Med 371(26): 2488-2498. 26 
James, C., V. Ugo, N. Casadevall, S. N. Constantinescu and W. Vainchenker (2005). "A JAK2 mutation 27 
in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects." Trends Mol 28 
Med 11(12): 546-554. 29 
Kiladjian, J. J., B. Cassinat, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, M. L. Menot, G. Massonnet, 30 
J. L. Dutel, K. Ghomari, P. Rousselot, M. J. Grange, Y. Chait, W. Vainchenker, N. Parquet, L. 31 
Abdelkader-Aljassem, J. F. Bernard, J. D. Rain, S. Chevret, C. Chomienne and P. Fenaux (2006). "High 32 
molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a." 33 
Blood 108(6): 2037-2040. 34 
Kiladjian, J. J., S. Chevret, C. Dosquet, C. Chomienne and J. D. Rain (2011). "Treatment of 35 
polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 36 
1980." J Clin Oncol 29(29): 3907-3913. 37 
Kjær, L., M. Westman, C. Hasselbalch Riley, E. Høgdall, O. Weis Bjerrum and H. Hasselbalch (2012). 38 
"A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele 39 
burden." PLoS One 7(3): e33100. 40 
Koopmans, S. M., F. J. Bot, K. H. Lam, A. M. van Marion, H. de Raeve and K. M. Hebeda (2011). 41 
"Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia." Am J Clin 42 
Pathol 136(4): 618-624. 43 
Lamy, T., A. Devillers, M. Bernard, A. Moisan, I. Grulois, B. Drenou, L. Amiot, R. Fauchet and P. Y. Le 44 
Prise (1997). "Inapparent polycythemia vera: an unrecognized diagnosis." Am J Med 102(1): 14-20. 45 
Landolfi, R., L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. Marfisi, G. Tognoni, R. Marchioli 46 
and E. C. o. L.-D. A. i. P. V. (ECLAP) (2007). "Leukocytosis as a major thrombotic risk factor in patients 47 
with polycythemia vera." Blood 109(6): 2446-2452. 48 
Landolfi, R., R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni, C. Patrono, T. Barbui and E. C. o. L.-D. A. i. 49 
P. V. Investigators (2004). "Efficacy and safety of low-dose aspirin in polycythemia vera." N Engl J 50 
Med 350(2): 114-124. 51 
36 
 
Larsen, T. S., M. B. Møller, K. de Stricker, P. Nørgaard, J. Samuelsson, C. Marcher, M. T. Andersen, O. 1 
W. Bjerrum and H. C. Hasselbalch (2009). "Minimal residual disease and normalization of the bone 2 
marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on 3 
molecular response patterns in seven patients in sustained complete hematological remission." 4 
Hematology 14(6): 331-334. 5 
Lawless, S., M. F. McMullin, R. Cuthbert and R. Houston (2016). "(32)P in the treatment of 6 
myeloproliferative disorders." Ulster Med J 85(2): 83-85. 7 
Madelung, A. B., H. Bondo, I. Stamp, P. Loevgreen, S. L. Nielsen, A. Falensteen, H. Knudsen, M. 8 
Ehinger, R. Dahl-Sørensen, N. B. Mortensen, K. D. Svendsen, T. Lange, E. Ralfkiaer, K. Nielsen, H. C. 9 
Hasselbalch and J. Thiele (2013). "World Health Organization-defined classification of 10 
myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish 11 
experience." Am J Hematol 88(12): 1012-1016. 12 
Marchioli, R., G. Finazzi, R. Landolfi, J. Kutti, H. Gisslinger, C. Patrono, R. Marilus, A. Villegas, G. 13 
Tognoni and T. Barbui (2005). "Vascular and neoplastic risk in a large cohort of patients with 14 
polycythemia vera." J Clin Oncol 23(10): 2224-2232. 15 
Marchioli, R., G. Finazzi, G. Specchia, R. Cacciola, R. Cavazzina, D. Cilloni, V. De Stefano, E. Elli, A. 16 
Iurlo, R. Latagliata, F. Lunghi, M. Lunghi, R. M. Marfisi, P. Musto, A. Masciulli, C. Musolino, N. 17 
Cascavilla, G. Quarta, M. L. Randi, D. Rapezzi, M. Ruggeri, E. Rumi, A. R. Scortechini, S. Santini, M. 18 
Scarano, S. Siragusa, A. Spadea, A. Tieghi, E. Angelucci, G. Visani, A. M. Vannucchi, T. Barbui and C.-P. 19 
C. Group (2013). "Cardiovascular events and intensity of treatment in polycythemia vera." N Engl J 20 
Med 368(1): 22-33. 21 
Mascarenhas, J., J. Prchal, A. Rambaldi, R. Messi, D. Berenzon, A. Yacoub, C. Harrison, M. McMullin, 22 
A. Vannuccchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. 23 
Arcasoy, C. Kessler, R. Catchatorian, D. Rondelli, R. Silver, E. Ritchie, A. Nagler, M. Kremyanskaya, R. 24 
Schlenk, R. Weinberg, M. Salama, G. Tognomi, G. Prosperini, A. Di Lelio, E. Serone, L. Marfisi, J. 25 
Kieczko, H. Kosiorek, T. Barbui, D. AC and H. R (2016 26 
 ). Interim analysis of the myeloproliferative disorders research consortium (MPD-RC) 112 global 27 
phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia 28 
vera and essential thrombocythemia, Blood. 128. 29 
McMullin, M. F., D. Bareford, P. Campbell, A. R. Green, C. Harrison, B. Hunt, D. Oscier, M. I. Polkey, J. 30 
T. Reilly, E. Rosenthal, K. Ryan, T. C. Pearson, B. Wilkins and G. H. T. F. o. t. B. C. f. S. i. Haematology 31 
(2005). "Guidelines for the diagnosis, investigation and management of 32 
polycythaemia/erythrocytosis." Br J Haematol 130(2): 174-195. 33 
McMullin, M. F., C. N. Harrison and J. J. Kiladjian (2013). "Treatment target in polycythemia vera." N 34 
Engl J Med 368(16): 1554-1555. 35 
McMullin, M. F., J. T. Reilly, P. Campbell, D. Bareford, A. R. Green, C. N. Harrison, E. Conneally, K. 36 
Ryan, M. e. D. S. National Cancer Research Institute and B. C. f. S. i. Haematology (2007). 37 
"Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis." Br J 38 
Haematol 138(6): 821-822. 39 
Mesa, R., A. M. Vannucchi, A. Yacoub, P. Zachee, M. Garg, R. Lyons, S. Koschmieder, C. Rinaldi, J. 40 
Byrne, Y. Hasan, F. Passamonti, S. Verstovsek, D. Hunter, M. M. Jones, H. Zhen, D. Habr and B. 41 
Martino (2017). "The efficacy and safety of continued hydroxycarbamide therapy versus switching to 42 
ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, 43 
symptom study (RELIEF)." Br J Haematol 176(1): 76-85. 44 
Passamonti, F., C. Elena, S. Schnittger, R. C. Skoda, A. R. Green, F. Girodon, J. J. Kiladjian, M. F. 45 
McMullin, M. Ruggeri, C. Besses, A. M. Vannucchi, E. Lippert, H. Gisslinger, E. Rumi, T. Lehmann, C. A. 46 
Ortmann, D. Pietra, C. Pascutto, T. Haferlach and M. Cazzola (2011). "Molecular and clinical features 47 
of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations." Blood 117(10): 2813-48 
2816. 49 
Passamonti, F., M. Griesshammer, F. Palandri, M. Egyed, G. Benevolo, T. Devos, J. Callum, A. M. 50 
Vannucchi, S. Sivgin, C. Bensasson, M. Khan, N. Mounedji and G. Saydam (2017). "Ruxolitinib for the 51 
37 
 
treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a 1 
randomised, open-label, phase 3b study." Lancet Oncol 18(1): 88-99. 2 
Passamonti, F., E. Rumi, D. Pietra, C. Elena, E. Boveri, L. Arcaini, E. Roncoroni, C. Astori, M. Merli, S. 3 
Boggi, C. Pascutto, M. Lazzarino and M. Cazzola (2010). "A prospective study of 338 patients with 4 
polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic 5 
disease transformation and vascular complications." Leukemia 24(9): 1574-1579. 6 
Pearson, T. C., D. L. Guthrie, J. Simpson, S. Chinn, G. Barosi, A. Ferrant, S. M. Lewis and Y. Najean 7 
(1995). "Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on 8 
Radionuclides of the International Council for Standardization in Haematology." Br J Haematol 89(4): 9 
748-756. 10 
Pearson, T. C. and G. Wetherley-Mein (1978). "Vascular occlusive episodes and venous haematocrit 11 
in primary proliferative polycythaemia." Lancet 2(8102): 1219-1222. 12 
Perricone, M., N. Polverelli, G. Martinelli, L. Catani, E. Ottaviani, E. Zuffa, E. Franchini, A. Dizdari, D. 13 
Forte, E. Sabattini, M. Cavo, N. Vianelli and F. Palandri (2017). "The relevance of a low JAK2V617F 14 
allele burden in clinical practice: a monocentric study." Oncotarget 8(23): 37239-37249. 15 
Pieri, L., A. Pancrazzi, A. Pacilli, C. Rabuzzi, G. Rotunno, T. Fanelli, P. Guglielmelli, R. Fjerza, C. Paoli, S. 16 
Verstovsek and A. M. Vannucchi (2015). "JAK2V617F complete molecular remission in polycythemia 17 
vera/essential thrombocythemia patients treated with ruxolitinib." Blood 125(21): 3352-3353. 18 
Quintás-Cardama, A., H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. 19 
Borthakur, M. Konopleva, J. Cortes and S. Verstovsek (2009). "Pegylated interferon alfa-2a yields 20 
high rates of hematologic and molecular response in patients with advanced essential 21 
thrombocythemia and polycythemia vera." J Clin Oncol 27(32): 5418-5424. 22 
Samuelsson, J., H. Hasselbalch, O. Bruserud, S. Temerinac, Y. Brandberg, M. Merup, O. Linder, M. 23 
Bjorkholm, H. L. Pahl, G. Birgegard and N. S. G. f. M. Disorders (2006). "A phase II trial of pegylated 24 
interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, 25 
clinical and biologic effects, and impact on quality of life." Cancer 106(11): 2397-2405. 26 
Santoro, C., I. Sperduti, R. Latagliata, E. Baldacci, B. Anaclerico, G. Avvisati, M. Breccia, F. Buccisano, 27 
M. Cedrone, G. Cimino, C. De Gregoris, M. De Muro, A. Di Veroli, S. Leonetti Crescenzi, M. 28 
Montanaro, E. Montefusco, R. Porrini, A. Rago, A. Spadea, F. Spirito, N. Villivà, A. Andriani, G. 29 
Alimena and M. G. Mazzucconi (2017). "Role of treatment on the development of secondary 30 
malignancies in patients with essential thrombocythemia." Cancer Med 6(6): 1233-1239. 31 
Scott, L. M., W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, 32 
M. F. McMullin, C. N. Harrison, A. J. Warren, D. G. Gilliland, H. F. Lodish and A. R. Green (2007). "JAK2 33 
exon 12 mutations in polycythemia vera and idiopathic erythrocytosis." N Engl J Med 356(5): 459-34 
468. 35 
Silver, R. T. (2006). "Long-term effects of the treatment of polycythemia vera with recombinant 36 
interferon-alpha." Cancer 107(3): 451-458. 37 
Silver, R. T., M. H. Bourla, K. Vandris, S. Fruchtman, J. L. Spivak, E. J. Feldman and A. J. Salvado (2012). 38 
"Treatment of polycythemia vera with imatinib mesylate." Leuk Res 36(2): 156-162. 39 
Stauffer Larsen, T., K. F. Iversen, E. Hansen, A. B. Mathiasen, C. Marcher, M. Frederiksen, H. Larsen, I. 40 
Helleberg, C. H. Riley, O. W. Bjerrum, D. Rønnov-Jessen, M. B. Møller, K. de Stricker, H. Vestergaard 41 
and H. C. Hasselbalch (2013). "Long term molecular responses in a cohort of Danish patients with 42 
essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant 43 
interferon alpha." Leuk Res 37(9): 1041-1045. 44 
Takahashi, K., K. P. Patel, H. Kantarjian, R. Luthra, S. Pierce, J. Cortes and S. Verstovsek (2013). "JAK2 45 
p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates 46 
in patients with myeloproliferative neoplasms." Blood 122(23): 3784-3786. 47 
Taylor, P. C., G. Dolan, J. P. Ng, B. Paul, R. Collin and J. T. Reilly (1996). "Efficacy of recombinant 48 
interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of 49 
published data." Br J Haematol 92(1): 55-59. 50 
38 
 
Tefferi, A., T. L. Lasho, P. Guglielmelli, C. M. Finke, G. Rotunno, Y. Elala, A. Pacilli, C. A. Hanson, A. 1 
Pancrazzi, R. P. Ketterling, C. Mannarelli, D. Barraco, T. Fanelli, A. Pardanani, N. Gangat and A. M. 2 
Vannucchi (2016). "Targeted deep sequencing in polycythemia vera and essential 3 
thrombocythemia." Blood Adv 1(1): 21-30. 4 
Tefferi, A., E. Rumi, G. Finazzi, H. Gisslinger, A. M. Vannucchi, F. Rodeghiero, M. L. Randi, R. Vaidya, 5 
M. Cazzola, A. Rambaldi, B. Gisslinger, L. Pieri, M. Ruggeri, I. Bertozzi, N. H. Sulai, I. Casetti, A. 6 
Carobbio, G. Jeryczynski, D. R. Larson, L. Müllauer, A. Pardanani, J. Thiele, F. Passamonti and T. 7 
Barbui (2013). "Survival and prognosis among 1545 patients with contemporary polycythemia vera: 8 
an international study." Leukemia 27(9): 1874-1881. 9 
Tefferi, A., J. J. Strand, T. L. Lasho, R. A. Knudson, C. M. Finke, N. Gangat, A. Pardanani, C. A. Hanson 10 
and R. P. Ketterling (2007). "Bone marrow JAK2V617F allele burden and clinical correlates in 11 
polycythemia vera." Leukemia 21(9): 2074-2075. 12 
Thiele, J., H. M. Kvasnicka and V. Diehl (2005). "Bone marrow features of diagnostic impact in 13 
erythrocytosis." Ann Hematol 84(6): 362-367. 14 
Vannucchi, A. M. (2015). "Ruxolitinib versus standard therapy for the treatment of polycythemia 15 
vera." N Engl J Med 372(17): 1670-1671. 16 
Vannucchi, A. M., E. Antonioli, P. Guglielmelli, G. Longo, A. Pancrazzi, V. Ponziani, C. Bogani, P. R. 17 
Ferrini, A. Rambaldi, V. Guerini, A. Bosi, T. Barbui and M. R. Consortium (2007). "Prospective 18 
identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden." Leukemia 19 
21(9): 1952-1959. 20 
Vannucchi, A. M., S. Verstovsek, P. Guglielmelli, M. Griesshammer, T. C. Burn, A. Naim, D. 21 
Paranagama, M. Marker, B. Gadbaw and J. J. Kiladjian (2017). "Ruxolitinib reduces JAK2 p.V617F 22 
allele burden in patients with polycythemia vera enrolled in the RESPONSE study." Ann Hematol 23 
96(7): 1113-1120. 24 
Verstovsek, S., C. N. Harrison, J. J. Kiladjian, C. Miller, A. B. Naim, D. C. Paranagama, D. Habr and A. 25 
M. Vannucchi (2017). "Markers of iron deficiency in patients with polycythemia vera receiving 26 
ruxolitinib or best available therapy." Leuk Res 56: 52-59. 27 
Verstovsek, S., F. Passamonti, A. Rambaldi, G. Barosi, P. J. Rosen, E. Rumi, E. Gattoni, L. Pieri, P. 28 
Guglielmelli, C. Elena, S. He, N. Contel, B. Mookerjee, V. Sandor, M. Cazzola, H. M. Kantarjian, T. 29 
Barbui and A. M. Vannucchi (2014). "A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, 30 
in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea." 31 
Cancer 120(4): 513-520. 32 
Whitehead, T. P., D. Robinson, S. L. Allaway and A. C. Hale (1995). "The effects of cigarette smoking 33 
and alcohol consumption on blood haemoglobin, erythrocytes and leucocytes: a dose related study 34 
on male subjects." Clin Lab Haematol 17(2): 131-138. 35 
 36 
